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We report significant failure rates (28%, 95% confi-
dence interval 15%–45%) after administering 1 g
azithromycin to men with Mycoplasma genitalium–positive
nongonococcal urethritis. In vitro evidence supported
reduced susceptibility of M. genitalium to macrolides.
Moxifloxacin administration resulted in rapid symptom res-
olution and eradication of infection in all cases. These find-
ings have implications for management of urethritis.
M
ycoplasma genitalium has been well described as a
pathogen in men with acute and chronic nongono-
coccal urethritis (NGU) and has been associated with cer-
vicitis in women (1). Since culturing the organism is
difficult, limited information has been available regarding
its antimicrobial drug susceptibility. In vitro studies sug-
gest it is susceptible to tetracyclines, macrolides, and fluo-
roquinolones (2–4), although reduced susceptibility to
tetracyclines (5) and specific fluoroquinolones has been
reported (4,6). In clinical studies, doxycycline and lev-
ofloxacin (4,7–11) have substantial failure rates, whereas
early reports suggest single-dose azithromycin may be
more efficacious (10,11). Treatment guidelines for acute
NGU include 1 g single dose of azithromycin or doxycy-
cline for 7 days, but no evidence-based guidelines exist for
treatment of M. genitalium–positive NGU.
We report treatment failure of single-dose and multi-
dose azithromycin therapy in M. genitalium–positive NGU
and provide in vitro evidence of macrolide resistance in
clinical isolates. Persistent infection was eradicated with
moxifloxacin.
The Study
Cases were derived from a case-control study of acute
NGU conducted from March 2004 to March 2005 at
Melbourne Sexual Health Centre (MSHC), Australia (12).
Participants completed a questionnaire, underwent exami-
nation, and had first-void urine samples analyzed by
strand-displacement amplification (ProbeTec-ET CT-
Amplified-DNA-Assay, Becton, Dickinson and Company,
Sparks, MD, NJ, USA) for Chlamydia trachomatis and by
polymerase chain reaction (PCR) for M. genitalium (13),
herpes simplex viruses (HSV-1 and -2), Trichomonas vagi-
nalis, Ureaplasma urealyticum and parvum, Gardnerella
vaginalis, and adenoviruses (12). Culture of urethral sam-
ples in modified-Thayer-Martin medium was performed
for Neisseria gonorrhoeae.
Men with M. genitalium infection were instructed
regarding partner notification and reinfection and were
asked to return for a test of cure (TOC) 1 month posttreat-
ment. Men with persistent M. genitalium infection were
given 1 g single dose of azithromycin or 1 g weekly for 3
doses, but after apparent failure of azithromycin therapy in
3 men without reinfection, participants with persistent
infection were offered moxifloxacin, 400 mg daily for 10
days. Four urethral specimens from men for whom
azithromycin therapy failed were inoculated into SP4
medium, frozen (–80°C), and shipped on dry ice to Statens
Serum Institut, Denmark, for culture in Vero cells and
antimicrobial drug susceptibility testing (6). M. genitalium
strains in Vero cell culture were grown in the presence of
different concentrations of antimicrobial drugs, and
growth of M. genitalium was monitored by quantitative
PCR for determination of MIC (6).
The Human Research and Ethics Committee of the
Alfred Hospital, Victoria, approved the study. Data were
stored in Microsoft Access and analyzed by using SPSS
version 12 (SPSS Inc., Chicago, IL, USA). Ninety-five
percent confidence intervals (CIs) were calculated for pro-
portions, which were compared by using the Fisher exact
test. Patients were excluded from the analysis when infor-
mation or specimens were not available.
M. genitalium was detected in 31(9.4%) of 329 patients
(95% CI 6.6%–12.9%) and 3 of 307 controls. No patients
with M. genitalium infection had other pathogens detected
(12). Men with M. genitalium had a median age of 33 years
(range 22–54 years); 25 were heterosexual, and 9 were
homosexual (behavioral and clinical data are presented
elsewhere [12]). Six female and 4 male asymptomatic sex-
ual contacts of M. genitalium–infected men were tested; a
throat and anal sample in 1 man and a cervical sample in 1
woman were positive for M. genitalium. Contacts were
presumptively treated with 1 g single dose of azithro-
mycin; however, the infected male contact required moxi-
floxacin after azithromycin treatment failed in this patient
and in the index patient.
Thirty-two men (94%) completed their TOC, a median
of 31 days (range 17–59 days) after receiving azithromycin.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 7, July 2006 1149
*Alfred Hospital, Victoria, Australia; †University of Melbourne,
Victoria, Australia; ‡Statens Serum Institut, Copenhagen,
Denmark; and §Royal Women’s Hospital, Victoria, AustraliaTwenty-three (72%) men had a negative TOC (95% CI
55%–85%) and were asymptomatic; however, 9 (28%,
95% CI 15%–45%) were positive for M. genitalium by
PCR. No treatment failures reported unprotected sexual
contact posttreatment or previous antimicrobial drugs.
Azithromycin treatment failed in 4 (44%, 95% CI
16%–76%) homosexual males, compared to 5 (22%, 95%
CI 8%–42%) heterosexual males (p = 0.23). Five men for
whom azithromycin treatment failed reported sexual con-
tact with partners from Asia before symptom onset (56%,
95% CI 24%–84%) compared to 6 azithromycin respon-
ders (27%, 12%–48%), p = 0.22. Eight patients for whom
azithromycin treatment failed reported an initial reduction
or resolution of symptoms following azithromycin and
then experienced recurrent urethral symptoms; 1 male was
persistently asymptomatic. The Table outlines urethral
Gram stain findings and treatment of men with persistent
infection; all 8 men became asymptomatic after receiving
moxifloxacin.
The 4 TOC specimens from men with azithromycin
failure available for culture yielded growth of M. genitali-
um. Antimicrobial drug susceptibility testing showed
increased MICs to macrolides: azithromycin >8 mg/L,
erythromycin >32 mg/L, and clarithromycin >32 mg/L. All
isolates were susceptible to moxifloxacin (MIC range
0.031–0.125 mg/L) and could be considered susceptible to
doxycycline (MIC range 0.125–0.25 mg/L). However,
correlates between in vitro MICs and treatment efficacy
have not yet been established.
Conclusions
The azithromycin failure rate in M. genitalium–positive
NGU was 28% (15%–45%) in this study and was associat-
ed with recurrent urethral symptoms in 8 of 9 cases.
Longer course azithromycin ameliorated but did not
resolve symptoms or eradicate infection, whereas moxi-
floxacin resulted in rapid symptom resolution and eradi-
cated infection. Symptom improvement followed by
recrudescence has been reported after levofloxacin failure
(9). Culture of M. genitalium from all 4 specimens, and
reduced susceptibility to azithromycin in vitro, demon-
strates that azithromycin-resistance rather than reinfection
caused treatment failure and that nonviable DNA was not
the reason for a persistently positive PCR. The availability
of strains in pure culture will enable investigation into
resistance mechanisms, and work in progress indicates that
mutations in region-V of the 23S-rDNA explain the
azithromycin resistance (J.S. Jensen, unpub. data).
M. genitalium has been associated with persistent NGU
(1). Recent data indicate that sequence variation in the
gene mediating adhesion to epithelial cells coincides with
the immune response in patients and that changes in this
gene occur rapidly with persistent infection (14). In vitro
studies also suggest that macrolide-resistant mutants can
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hibitory concentrations of macrolide (15). Macrolide
resistance in our study could have been induced by single-
dose azithromycin, which may be suboptimal for eradica-
tion of a slow-growing bacterium such as M. genitalium.
Studies are ongoing to establish whether resistance in our
isolates was present pretreatment or emerged after
azithromycin-exposure. It is possible that initial use of
higher doses or longer durations of azithromycin in M.
genitalium-positive NGU could avoid selection of resistant
mutants. The association between azithromycin failure and
sexual partners from Asia may be clinically relevant, given
the high levels of antimicrobial drug resistance reported in
other sexually transmitted infections such as Neisseria
gonorrhoeae infections in Asia, and the higher failure rates
seen in homosexual men, while not statistically significant,
may represent a core-group effect.
Azithromycin or doxycycline is recommended treat-
ment for NGU. While treatment-failure in M. genitalium–
positive NGU appears common with doxycycline (4,7–11),
early reports suggest 1 g azithromycin is more effective,
with cure rates of 85% (10,11), and that prolonged
azithromycin treatment (500 mg on day 1 and 250 mg on
days 2–5) eradicates M. genitalium in 95% of cases (10).
However, if treatment-failure after 1 g azithromycin is as
prevalent as indicated by our study in M. genitalium–posi-
tive NGU, this has implications for the use of single-dose
azithromycin as first-line treatment for NGU and leaves
few evidence-based treatment options. Information regard-
ing sensitivity of M. genitalium to fluoroquinolones has
been limited, but reports suggest differential activity
against M. genitalium, with levofloxacin (4,9) less active
than gatifloxacin, sparfloxacin, and tosufloxacin in vitro
and in vivo and moxifloxacin more active than lev-
ofloxacin and ciprofloxacin in vitro (6).
We report significant failure rates of azithromycin in M.
genitalium–positive NGU that is supported by in vitro evi-
dence of reduced susceptibility to macrolides. Recurrent
urethral symptoms following azithromycin therapy only
occurred in persons with persistent M. genitalium infection
and resolved with moxifloxacin.
Because single-dose azithromycin is recommended
treatment for NGU, these findings have implications for
treatment guidelines and highlight the need for random-
ized studies to determine optimal treatment for M. genital-
ium–positive NGU and M. genitalium infection in women,
who are at high risk for sequelae.
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